PSEUDOTYPED VIRAL PARTICLES, COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF

Abstract

Provided for herein are mutant VSV-G polypeptides, compositions comprising the same, and methods of using the same. Also provided for herein are polypeptides and compositions that bind to CD7 and uses thereof. Also provided for herein are polypeptides and compositions that bind to CD8 and uses thereof.

Description

Claims

1-70. (canceled)

71. A polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 2 and comprises a mutation that corresponds to a mutation at position 182 of SEQ ID NO: 2.

72. The polypeptide of claim 1, wherein the polypeptide comprises an amino acid sequence that is at least 96% identical to the amino acid sequence of SEQ ID NO: 2 and comprises a mutation that corresponds to a mutation at position 182 of SEQ ID NO: 2.

73. The polypeptide of claim 1, wherein the polypeptide comprises an amino acid sequence that is at least 97% identical to the amino acid sequence of SEQ ID NO: 2 and comprises a mutation that corresponds to a mutation at position 182 of SEQ ID NO: 2.

74. The polypeptide of claim 1, wherein the polypeptide comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 2 and comprises a mutation that corresponds to a mutation at position 182 of SEQ ID NO: 2.

75. The polypeptide of claim 1, wherein the polypeptide comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO: 2 and comprises a mutation that corresponds to a mutation at position 182 of SEQ ID NO: 2.

76. The polypeptide of claim 1, wherein the mutation at position is a I182E mutation as compared to SEQ ID NO: 2.

77. The polypeptide of claim 1, wherein the mutation at position 182 comprises a I182D mutation as compared to SEQ ID NO: 2.

78. The polypeptide of claim 1, wherein the polypeptide further comprises a mutation that corresponds to a mutation at position 214, a mutation at position 352, or a mutation at both position 214 and position 352 of SEQ ID NO: 2.

79. The polypeptide of claim 1, wherein the polypeptide further comprises a T214N mutation, a T352A mutation, or a combination thereof, as compared to SEQ ID NO: 2.

80. The polypeptide of claim 1, wherein the polypeptide further comprises a T214N mutation and a T352A mutation as compared to SEQ ID NO: 2.

81. The polypeptide of claim 1, wherein the mutation at position 182 comprises a I182E or I182D mutation as compared to SEQ ID NO: 2 and wherein the polypeptide further comprises a T214N mutation, a T352A mutation, or a combination thereof, as compared to SEQ ID NO: 2.

82. The polypeptide of claim 1, wherein the mutation at position 182 comprises a I182E mutation as compared to SEQ ID NO: 2 and wherein the polypeptide further comprises a T214N mutation, a T352A mutation, or a combination thereof, as compared to SEQ ID NO: 2.

83. The polypeptide of claim 1, wherein the mutation at position 182 comprises a I182E or I182D mutation as compared to SEQ ID NO: 2 and wherein the polypeptide further comprises a T214N mutation and a T352A mutation as compared to SEQ ID NO: 2.

84. The polypeptide of claim 1, wherein the mutation at position 182 comprises a I182E mutation as compared to SEQ ID NO: 2 and wherein the polypeptide further comprises a T214N mutation and a T352A mutation as compared to SEQ ID NO: 2.

85. The polypeptide of claim 1, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 23.

86. A nucleic acid molecule encoding the polypeptide of claim 1.

87. A vector comprising the nucleic acid molecule of claim 86.

88. A cell comprising the nucleic acid molecule of claim 86.

89. A viral particle comprising the polypeptide of claim 1.

90. The viral particle of claim 89, wherein the viral particle is a lentivirus comprising the polypeptide.

91. The viral particle of claim 89, wherein the viral particle further comprises a heterologous nucleic acid molecule encoding a heterologous molecule of interest.

92. The viral particle of claim 91, wherein the heterologous molecule of interest is an siRNA, an shRNA, a non-coding RNA, a polypeptide, a viral payload, a viral genome, or a combination thereof.

93. The viral particle of claim 91, wherein the heterologous molecule of interest is a chimeric antigen receptor (“CAR”).